NeuroStim Solutions
United StatesSee on the mapFounded 2025
- Neuromodulation
- Series B
NeuroStim Solutions provides hands-on strategic and interim leadership for neuromodulation start-ups and scale-ups. Led by Dave Mugan, it helps companies turn complex science into credible clinical, regulatory, fundraising, and commercial strategies, drawing on more than 20 years of neuromodulation experience.
- RaisedTotal raised
- $123M
- Nov 2026Latest priced round, Nov 2026
- Series B
- Investors
- 6
- Founded
- 2025
- Employees
- 0–1
reccy insights
NeuroStim Solutions is described as providing hands-on strategic and interim leadership to neuromodulation start-ups and scale-ups, led by founder Dave Mugan. The company’s stated experience includes more than 20 years in neuromodulation, work spanning first-in-human studies through regulatory approval, and expertise across clinical, regulatory, fundraising, and commercial strategy. Its funding history includes a $1,756,454 grant dated Jul 15, 2023, a $5,802,221 Series A dated Oct 13, 2023, and a separate $10 million undisclosed round on that same date. A $105 million Series B dated Nov 11, 2026 lists Perceptive Advisors, RTW Investments, Janus Henderson Investors, Affinity Asset Advisors, and Google Ventures as lead investors. There is also a notable identity and financial-data inconsistency: the company profile is named NeuroStim Solutions, while financial information uses the name Scion NeuroStim, and the stated $10 million total does not reconcile with the listed rounds. The shared website domain supports a connection, but the discrepancy warrants caution.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
What makes NeuroStim Solutions distinct
- 01More than 20 years of experience dedicated to neuromodulation.
- 02Supports companies from early concepts and first-in-human studies through regulatory approval and early commercialisation.
- 03Combines clinical, regulatory, fundraising, and commercial expertise in a practical, hands-on advisory approach.
- 04Founder Dave Mugan has led first-in-human clinical and basic science programmes and is described as an author of peer-reviewed publications and a named inventor on multiple patents.
- 05Emphasizes clear, evidence-grounded communication rather than hype.
Funding
- Series BNov 2026$105MLed by Perceptive Advisors, RTW Investments, Janus Henderson Investors, Affinity Asset Advisors, Google Ventures
- Series AOct 2023$5.8M
- UndisclosedOct 2023$10M
Investors6
- Affinity Asset Advisors
Similar companies
About NeuroStim Solutions
- Leadership
- Dave Mugan
- Focus areas
- NeuroTechnology, medical devices, clinical research, neuromodulation, clinical strategy, regulatory strategy, fundraising advisory, commercialisation
- Headquarters
- United States
- Founded
- 2025
- Employees
- 0–1